Ikena Oncology
Latest round
- Series B
Last raised
- Jan 2021
Total raised
- $169M
Investors
- 12
About Ikena Oncology
, formerly known as Kyn Therapeutics, operates as a biotechnology company.D.D.81 million shares at USD 16 per share on the Nasdaq. The company will be publicly listed on the Nasdaq Global Select Market under the ticker symbol "IMA". Ikena Oncology is a clinical-stage biotechnology company that focuses, discovers, and develops patient-directed, biomarker-driven therapies for cancer patients who need life-saving treatment, by understanding what drives their disease. Ikena is advancing five clinical, preclinical, and discovery programs: IK-930, a TEAD inhibitor targeting the Hippo signaling pathway; a lead optimization-stage KRAS signaling program; IK-175, an AHR antagonist; IK-412, a kynurenine-degrading enzyme; and IK-007, an EP4 receptor antagonist. Ikena has entered into a global strategic collaboration with Bristol Myers Squibb on the IK-175 and IK-412 programs. Ikena Oncology plans to list on the Nasdaq under the symbol IKNA.
Who invested in Ikena Oncology
12 investors across 2 rounds
See all investors in Ikena Oncology
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Ikena Oncology
Who invested in Ikena Oncology?
Ikena Oncology has 12 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Ikena Oncology raised?
Ikena Oncology has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Ikena Oncology last raise money?
Ikena Oncology's most recent round on record is a Series B, in Jan 2021.
What does Ikena Oncology do?
, formerly known as Kyn Therapeutics, operates as a biotechnology company.
Where is Ikena Oncology headquartered?
Ikena Oncology is headquartered in Boston, US.
Which VCs invest in companies like Ikena Oncology?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Ikena Oncology's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Ikena Oncology? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.